Sunday
Research Workshops |
|
|
| EM - 1 |
HCV: Molecular Virology and Mechanisms of Clearance |
Barbara Rehermann, MD
Kenneth E. Sherman, MD, PhD
|
| EM - 2 |
HCV as a Metabolic Disease |
Steven A. Weinman, MD, PhD
Mandana Khalili, MD
|
| EM - 3 |
Alcoholic Liver Disease (BASIC) |
Samir Zakhari, PhD
Gavin E. Arteel, PhD
|
| EM - 4 |
Bilirubin Biology |
Peter L. M. Jansen, MD, PhD
Jayanta Roy Chowdhury, MD
|
| EM - 5 |
Hepatitis B: Molecular Virology and Disease Pathogenesis |
Mei-Hwei Chang, MD
Stephen Locarnini, MD, PhD
|
| EM - 6 |
Cholestasis: Molecular Mechanisms of Hepatotoxicity |
Laura Bull, PhD
John Chiang, PhD
|
| EM - 7 |
Iron Metabolism: Physiology and Molecular Biology |
Kris V. Kowdley, MD
John K. Olynyk, MD, PhD
|
| EM - 8 |
Mechanisms of Circulatory Dysfunction in Cirrhosis |
Don C. Rockey MD
Michael B. Fallon, MD
|
| EM - 9 |
Cholangiocyte Biology |
Mario Strazzabosco, MD, PhD
Gianfranco Alpini, PhD
|
Sunday
Clinical Management Workshops |
|
|
| EM -10 |
Tailoring HCV Treatment to the Individual Patient |
Michael W. Fried, MD
John G. McHutchison, MD
|
| EM - 11 |
HCV: Emerging Treatments |
David R. Nelson, MD
Gregory T. Everson, MD
|
| EM - 12 |
HBV Treatment: Prevention and Management of Resistance |
Anna S.F. Lok, MD
Tram Tran, MD
|
| EM - 13 |
Clinical Challenges: HIV-HCV Co-infection |
Richard K. Sterling, MD
Alexander Monto, MD
|
| EM - 14 |
NASH: Emerging Therapies |
Brent A. Tetri, MD
Kiran Bambha, MD
|
| EM - 15 |
Using Non-invasive Methods to Diagnose and Stage Liver Disease |
Vlad Ratziu, MD
Nezam H. Afdhal, MD
|
| EM - 16 |
Managing Immunosuppression after Liver Transplantation |
Jeffrey S. Crippin, MD
David J. Reich, MD
|
| EM - 17 |
Managing Viral Hepatitis Following Liver Transplantation |
Norah Terrault, MD
Marina Berenguer, MD
|
| EM - 18 |
Strategies and Outcomes of Expanded Donor Pool for Liver Transplantation |
Russell H. Wiesner, MD
Thomas D. Schiano, MD
|
Monday
Research Workshops |
|
|
| EM - 19 |
Angiogenesis and Cirrhosis |
Vijay Shah, MD
Anna Mae Diehl, MD
|
| EM - 20 |
Neurobiology of Cerebral Dysfunction in Liver Disease |
Roger F. Butterworth, PhD
Rajiv Jalan, MD
|
| EM - 21 |
Disorders of Hepatic Lipid Metabolism |
Michael Fuchs, MD, PhD
Richard M. Green, MD
|
| EM - 22 |
Regulation of Cholesterol and Bile Acid Metabolism |
David E. Cohen, MD, PhD
William Pandak, MD
|
| EM - 23 |
NASH: Mechanisms of Cell Injury and Disease Progression |
Mary E. Rinella, MD
Frank A. Anania, MD
|
| EM - 24 |
Drug Induced Hepatotoxicity |
Hartmut W. Jaeschke, PhD
Wajahat Z. Mehal, MD
|
| EM - 25 |
Nuclear Receptors |
Frederick J. Suchy, MD
Michael Trauner, MD
|
| Monday Clinical Management Workshops |
|
|
|
EM - 26
|
Designing Clinical Trials for NAFLD: Opportunities and Pitfalls |
Naga P. Chalasani, MD
Elizabeth M. Brunt, MD |
|
EM - 27
|
Prevention and Treatment of Renal Failure Before and After Liver Transplantation |
Pere Gines, MD
K. Rajender Reddy, MD |
|
EM - 28
|
Fatty Liver Disease in Children: Implications for Adult Hepatologists |
Jeffrey Schwimmer, MD
Philip Rosenthal, MD |
|
EM - 29
|
Metabolic Liver Disease |
Michael L. Schilsky, MD
Kris V. Kowdley, MD |
|
EM - 30
|
Minimal Hepatic Encephalopathy |
Kevin D. Mullen, MD
Charmaine A. Stewart, MD |
|
EM - 31
|
Emerging Trends and Treatment in Acute Liver Failure |
Richard T. Stravitz, MD
Ann M. Larson, MD |
|
EM - 32
|
Management and Challenges for Liver Disease in Ethnic Subpopulations |
Charles D. Howell, MD
Maribel Rodriguez-Torres, MD |
|
EM - 33
|
Challenges to Implementation of Practice Guidelines in Liver Disease |
Hal F. Yee, MD, PhD
Hashem B. El-Serag, MD |
|
EM - 34
|
Pre-Transplant Management of HCC |
Francis Yao, MD
Laura M. Kulik, MD |
|
EM - 35
|
Liver Disease and Pregancy (Clinical) |
Ran Oren, MD
Karen Davidson, MD |
| Tuesday Research Workshops |
|
|
|
EM - 36
|
Stem Cells |
Linda Greenbaum, MD
Carl B. Rountree, Jr., MD |
|
EM - 37
|
HCC: Mechanisms of Carcinogenesis |
Satdarshan (Paul) S. Monga, MD
Lewis R. Roberts, MD, PhD |
|
EM - 38
|
Role of Kupffer Cells in Liver Disease |
Craig J. McClain, MD
Laura E. Nagy, PhD |
|
EM - 39
|
Mitochondrial Dysfunction and Liver Disease |
John J. Lemasters, MD, PhD
Stephen H. Caldwell, MD |
|
EM - 40
|
MicroRNA: Role in Health and Disease |
Tushar Patel, MD
Clifford J. Steer, MD |
|
EM - 41
|
Hepatic Inflammation and Innate Immunity |
Gyongyi Szabo, MD, PhD
Zhiping Li, MD |
|
EM - 42
|
Mechanisms of Cell Death |
Trautwein Christian, MD
Ariel E. Feldstein, MD |
|
EM - 43
|
Fibrosis: Mechanisms |
Detlef Schuppan, MD, PhD
Meena B. Bansal, MD |
|
EM - 44
|
|
|
| Tuesday Clinical Management Workshops |
|
|
|
EM - 45
|
HCC Treatment: Role of Resection vs. Transplant |
Sasan Roayaie, MD
Francis Yao, MD |
|
EM - 46
|
Novel Therapeutic Targets for HCC |
James R. Spivey, MD
Jorge A. Marrero, MD |
|
EM - 47
|
Screening Asymptomatic Populations for Liver Disease: Approaches and Implications |
W. Ray Kim, MD
Miriam J. Alter, MD |
|
EM - 48
|
Noncancerous Nodular Lesions of the Liver: Diagnosis and Treatment |
Julie Heimbach, MD |
|
EM - 49
|
Difficult to Manage Ascites |
Bruce A. Runyon, MD
Hugo E. Vargas, MD |
|
EM - 50
|
Modeling Outcomes in Liver Disease |
Scott W. Biggins, MD
Douglas M. Heuman, MD |
|
EM - 51
|
Biliary Atresia |
Ronald J. Sokol, MD
John C. Bucuvalas, MD |
|
EM - 52
|
Emerging Treatment of Cholestasis and Cholestatic Disorders |
Ulrich Beuers, MD
Saul J. Karpen, MD, PhD |